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Abstract
Background: Group B Streptococcus (GBS) is the leading cause of neonatal sepsis in the developed world. Little is
known about its epidemiology in the developing world, where the majority of deaths from neonatal infections
occur. Maternal carriage of GBS is a prerequisite for the development of early onset GBS neonatal sepsis but there
is a paucity of carriage data published from the developing world, in particular South East Asia.
Methods: We undertook a cross sectional study over a 13 month period in a remote South East Asian setting on
the Thai-Myanmar border. During labour, 549 mothers had a combined vaginal rectal swab taken for GBS culture.
All swabs underwent both conventional culture as well as PCR for GBS detection. Cultured GBS isolates were
serotyped by latex agglutination, those that were negative or had a weak positive reaction and those that were
PCR positive but culture negative were additionally tested using multiplex PCR based on the detection of GBS
capsular polysaccharide genes.
Results: The GBS carriage rate was 12.0% (95% CI: 9.4-15.0), with 8.6% positive by both culture and PCR and an
additional 3.5% positive by PCR alone. Serotypes, Ia, Ib, II, III, IV, V, VI and VII were identified, with II the
predominant serotype. All GBS isolates were susceptible to penicillin, ceftriaxone and vancomycin and 43/47
(91.5%) were susceptible to erythromycin and clindamycin.
Conclusions: GBS carriage is not uncommon in pregnant women living on the Thai-Myanmar border with a large
range of serotypes represented.
Background
Each year four million neonates die from neonatal sepsis,
the majority in the first week of life in the developing
world [1]. Group B streptococcus (GBS, Streptococcus
agalactiae) is a leading cause of neonatal sepsis in the
developed world [2,3]. Historically, infection with GBS
has been reported to be rare in the developing world;
however its importance as a cause of neonatal sepsis in
these countries is being increasingly recognised [4-9].
An estimated 20-30% of women are colonized by GBS
in developed countries; however there is a paucity of
data regarding GBS colonization in the developing
world and in particular South East Asia [10-12]. This is
an important gap in knowledge. Not only is there a
large geographical variation in both carriage rates and
serotype distributions, but also GBS carriage varies tem-
porally [13]. Maternal carriage of GBS is necessary for
early neonatal infection to occur, with the gastrointest-
inal tract being the primary site of colonization [14].
Transmission is thought to occur just before or during
birth when GBS ascends the genital tract into the
amniotic fluid where it is aspirated or ingested by the
infant [12]. Intrapartum antibiotics given to women
colonized with GBS have been shown to reduce the inci-
dence of early onset GBS neonatal sepsis [15]. Various
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are used globally, with risk-based IPA administration in
the UK and a universal culture based screening program
in the USA [16,17]. The introduction of intrapartum
antibiotics in the developing world could reduce the
number of infants who die from neonatal sepsis each
year. However to determine the likely impact and the
optimal strategy of antibiotic administration the coloni-
zation prevalence and neonatal infection rate for GBS in
the target population should be known. Another poten-
tial strategy for GBS prevention is the introduction of a
GBS vaccine. Current candidates are polysaccharide pro-
tein conjugates so knowledge of the serotype distribu-
tion of GBS in different geographical areas will be
important in planning their implementation.
The aim of this study was to describe the GBS coloni-
zation rate, serotype distribution and antibiotic sensitiv-
ity profile in a rural population in South East Asia.
Methods
Maela Camp for displaced persons is a densely popu-
lated camp predominantly inhabited by Karen refugees
from Myanmar (Burma). It is located in North West
Thailand in the hills adjoining the Myanmar border 60
km north of Mae Sot. It is the largest of the camps for
displaced people on the Thai-Myanmar border, housing
around one-third of the total refugee population. Maela
has a population of approximately 43,000 people, living
in an area of 4 km
2. The Shoklo Malaria Research Unit
(SMRU) clinic provides all antenatal care in the camp,
where 1500 deliveries occur each year.
We conducted a cross sectional GBS carriage study at
the SMRU clinic between April 2009 and May 2010. All
women who attended the antenatal clinic and were
between 28 and 30 weeks gestation were asked to parti-
cipate. Women were asked to deliver at the SMRU clinic
so that a vaginal-rectal swab, a venous blood sample and
umbilical cord blood could be obtained during labour. It
is not possible to carry out Caesarean sections in the
camp so all infants are born vaginally. A standard pro-
forma was completed after delivery to determine ethnic
group, past obstetric history, recent antibiotic exposure,
and complications occurring during labour, concentrat-
ing on the risk factors for neonatal GBS infection (fever
> 38C, prolonged rupture of membranes, prematurity (<
37 weeks) that are included in risk based strategy for
the prevention of GBS neonatal sepsis [16]. All infants
were reviewed at planned study visits at seven and 28
days and at unplanned sick visits, to determine the inci-
dence of neonatal mortality and neonatal sepsis.
Detection of GBS carriage by culture
Combined vaginal-rectal swabs were collected and pro-
cessed following the CDC guideline [17]. Briefly, a
combined vaginal-rectal swab was collected using a ster-
ile swab with Amie’s transport medium (Transwab,
Medical Wire & Equipment, Corsham, UK). These
swabs were refrigerated until culture on the day of col-
lection. The swab tip was cultured overnight at 36°C in
5% CO2 in 5 ml LIM broth (Todd-Hewitt broth + colis-
tin and nalidixic acid; prepared in-house). A 5 μL loop
of this broth was subsequently sub-cultured on to 5%
sheep blood agar (Clinical Diagnostics, Bangkok, Thai-
land) and incubated for 24-48 hours at 36°C in 5% CO2.
Morphologically suspected GBS colonies were confirmed
by Gram’s stain, catalase reaction, and Lancefield group-
ing by latex agglutination (Streptococcus Grouping kit,
Oxoid, Basingstoke, UK). Antimicrobial susceptibilities
were determined by disc diffusion following 2009 CLSI
methodology [18]. All GBS isolates were serotyped by
latex agglutination (Strep-B-Latex kit, Statens Serum
Institute, Copenhagen Denmark). Those isolates that
were non-typeable by this serotyping method or had a
weak positive reaction were sent to the Health Protec-
tion Agency Microbiology Services Division Colindale,
Streptococcus and Diphtheria Reference Unit for further
characterisation using multiplex PCR assays based on
the detection of GBS capsular genotypes (Ia, Ib-IX) [19].
Detection of GBS carriage by polymerase chain reaction
(PCR)
A 1 mL aliquot of the cultured LIM broth was stored at
-80°C for subsequent Group B Streptococcal PCR. DNA
was extracted from 200 μL of the broth specimens using
the Bacterial DNA kit for the MagCore HF16 automated
nucleic acid extractor (RBC Bioscience, Taipei, Taiwan).
The real-time cfb gene PCR protocol developed by Ke et
al. was modified for use with a Rotorgene 6000 instru-
ment (Corbett Life Science, Australia) [20]. Briefly, the
PCR primers (Sag59 and Sag190) were identical to those
used in the original method, but a novel Taqman probe
(sequence: 5’-CATGCTGATCAAGTGACAACTC-
CACA-3’) was developed. This modified assay was
demonstrated to be GBS-specific and to have a limit of
detection of < 1 GBS cfu/reaction (unpublished data).
All PCRs were run with a negative and positive control
(clinical GBS isolate); specimen cT values of < 40, with
appropriate run controls, were considered positive.
Broth DNA extraction was repeated and PCR rerun in
all specimens with a first cT value of 35-39, and only
those with repeated low positive cT values and an
appropriate size band on agarose gel electrophoresis
were considered positive.
With the exception of PCR capsular genotyping, all
laboratory work was performed at the SMRU microbiol-
ogy laboratory in Mae Sot, Thailand: this laboratory
submits to the Thailand national microbiology DMSc
NEQAS scheme (unit code MI 1158).
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Data were entered into an Access 2003 database (Micro-
soft, Redmond WA, USA) and all statistical analyses car-
ried out using STATA 10.1 (StataCorp, College Station
TX, USA). The Student’s t-test was used to compare
means and the two-sample Wilcoxon rank sum to com-
pare medians. The Chi-squared test was used to com-
pare proportions, with two-tailed p-values of < 0.05
indicating significance.
Study ethics
All women gave informed consent to participate in the
study. Ethical approval was granted by the Ethics Com-
mittee of The Faculty of Tropical Medicine, Mahidol
University, Thailand (MUTM 2009-011-03) and the
Oxford Tropical Research Ethics Committee, Oxford
University, UK (48 08).
Results
Six hundred and seventy five women were enrolled over
the 13 month study period. During labour, 549 women
had vaginal-rectal swabs taken; 126 swabs were not
obtained as 14 women (2%) were lost during pregnancy
and 112 (17%) delivered outside of the SMRU clinic.
Epidemiological data for the women who had swabs
taken are shown in Table 1; characteristics did not differ
between those women who had a swab and those
women who did not (data not shown). There were a
total of 553 live births and three still births. Of the 549
swabs obtained 47/549 (8.6% [95% CI: 6.4-11.2]) were
found to be positive for GBS by culture with an addi-
tional 19 samples positive by PCR, making the overall
GBS carriage rate 66/549 (12.0% [95% CI: 9.4-15.0]).
Comparing culture to PCR, the sensitivity of culture was
71% (Table 2). There were no swabs that were GBS cul-
ture positive but PCR negative.
None of the risk factors that form the basis of a GBS
risk based IPA strategy (fever, prolonged rupture of
membranes, prematurity) were shown to be significantly
associated with GBS carrier status (≥ 1f a c t o ri n1 7 %
carriers vs. 18% in non-carriers (p = 0.7), Table 3) [16].
None of the mothers were known to have previously
had a baby with GBS disease. Overall therefore, 100/549
(18.2%) women had one or more clinical risk factors.
During labour 44/549 (8%) women received antibiotics:
ampicillin was the most commonly prescribed (95%).
Only one woman received erythromycin and none
received clindamycin. 39/44 (89%) women who received
antibiotics did so because of PROM; 2/44 (5%) for a
urinary tract infection; 1/44 (2%) for chorioamnionitis
and 2/44 (5%) for PROM and a urinary tract infection.
4/47 (8.5%) of the GBS culture positive mothers received
antibiotics, all of these were given for PROM. None of
the mothers who were GBS culture negative but PCR
positive received antibiotics during labour.
E i g h to ft h et e nc u r r e n t l yk n o w nG B Ss e r o t y p e sw e r e
identified, the most common being serotype II (16/66
isolates); the serotype distribution and frequency is
s h o w ni nF i g u r e1 .O ft h o s et h a tw e r ec u l t u r ep o s i t i v e
25/47 (53.2%) of serotypes were identified by latex
agglutination alone, with serotype III being the com-
monest detected. 4/47 (8.5%) were non typeable by latex
agglutination and subsequently were genotyped by PCR,
with all being identified as capsular genotype VI. Overall
18/47 (38.3%) showed a weak or mixed reaction with
latex agglutination but showed a clear capsular genotype
with PCR. This was particularly the case with capsular
genotype VI where none were clearly identified by latex
agglutination. Of the swabs that were culture negative
but PCR positive serotypes II and VI were the most fre-
quent (5/19, 26.3% each).
All GBS isolates were susceptible to penicillin, cef-
triaxone and vancomycin and 43/47 (91.5%) were sus-
ceptable to erythromycin and clindamycin.
Table 1 Ethnicity, previous number of pregnancies,
miscarriage and neonatal deaths for all women who had
a vaginal-rectal swab taken (n = 549)
















≥ 3 9 (1.6)
Missing 3 (0.6)
Previous Neonatal Death 14 (2.6)
Table 2 Comparison of PCR versus culture for GBS
detection
GBS PCR negative GBS PCR positive Total
GBS culture negative 483 19 502
GBS culture positive 04 7 4 7
Total 483 66 549
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neonatal death in infants born to women who were
colonized with GBS compared with those who were not
colonized. Of the 553 live born infants, 24 developed
clinical signs of early neonatal sepsis. Two of these
mothers were carriers of GBS (one serotype II and one
serotype III) but neither infant grew GBS from either
blood or CSF culture. No infant developed late onset
GBS sepsis, in fact there were no blood or CSF culture
proven episodes of sepsis. There were no early neonatal
deaths in infants born to mothers colonized with GBS
and only one late neonatal death at 18 days of age, from
an accident.
Discussion
This is the first GBS carriage study to be performed in a
rural South East Asian population and it adds to the
scant knowledge of GBS carriage in this region and the
developing world generally.
The GBS carriage rate in the pregnant women living
in Maela camp for displaced persons is 12%. Two pre-
vious studies carried out in Thailand showed GBS car-
riage rates of 16% and 18% [21,22]. The difference in
these rates is not unexpected as the study participants
were from different ethnic groups and geographic loca-
tions, with our study population being more reflective of
a developing world country such as Myanmar.
Table 3 Risk factors for GBS carriage
Risk Factor GBS carrier (n = 66) GBS negative (n = 483) P value
% (95% CI) % (95% CI)
Any risk factor 11 89 0.7
16.7 (8.6-27.9) 18.4 (15.1-22.2)
Fever > 38°C in labour 0 3 0.5
0.0 (0.0-5.4) 0.6 (0.1-1.8)
PROM > 18 hours 4 36 0.6
6.0 (1.7-14.8) 7.5 (5.3-10.2)
Preterm < 37 weeks 7 49 0.1
10.6 (4.4-20.6) 7.4 (5.3-10.2)
Fever and PROM 0 1 0.7
0.0 (0.0-5.4) 0.2 (0.0-1.1)
Fever and preterm 0 2 0.6
0.0 (0.0-5.4) 0.4 (0.0-1.5)
PROM and preterm 2 8 0.4
3.0 (0.4-10.0) 16.6 (0.1-3.2)
Preterm, PROM & fever 0 1 0.7
0.0 (0.0-5.4) 0.2 (0.0-1.1)
PROM prolonged rupture of membranes
Figure 1 Distribution of GBS capsular serotypes among 549 pregnant women at the time of delivery (*non-typeable).
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Page 4 of 6The rate of culture positive GBS carriage was found to
be lower than that detected by PCR. The PCR method
used in this study has been compared to standard culture
techniques and other PCR methods by Rallu et al. When
compared to the scpBP C R ,t h ecfb PCR was found to
have a sensitivity of 75.3% and culture a sensitivity of
42.3% [23]. Various hypotheses for this effect have been
suggested: antibiotics in the lead up to the time of the
swab or suppression of growth of GBS by enterococci
present in vaginal and rectal flora. In addition, there may
be difficulty in identifying GBS on culture due to over-
growth of Gram positive bacteria from the recto-vaginal
swab or due to a light growth of GBS [23,24].
Antibiotic susceptibility remains high in this popula-
tion with most isolates retaining susceptibility to the
macrolides despite reports of increasing erythromycin
and clindamycin resistance in GBS carriage isolates in
other regions [25]. This most probably reflects the low
use of these antibiotics in this population.
A large range of carried serotypes were identified, with
only a small number (4.5%) being non typeable. All of the
non typeable serotypes were on isolates identified by PCR
not on culture positive isolates, which raises the possibility
of false positive GBS cfb PCR results. However, the cT
values for these specimens were well within the expected
range. Four GBS culture positive isolates that were initially
non typeable by latex agglutination were subsequently
identified to be capsular genotype VI by PCR.
A recently published meta-analysis of geographical
GBS serotype distribution of carriage isolates, showed
that in Canada, North America and South America ser-
otype Ia was the predominant serotype. In Europe, the
Middle East, Africa, Australia and Asia serotype III pre-
dominated. Serotype II, which was the most common
serotype found in this study, was not found to be a pre-
dominate serotype in any region [26].
There is very little published data on GBS carriage in
Asia and in particular on the serotype distribution, how-
ever studies from Japan and Korea have described the
GBS serotype distributions in their populations [27,28].
In Korea the predominant serotype was serotype III
(20.3%), followed by serotype Ia (12.1%). In the Japanese
study serotype VIII was the most common serotype
making up 35.6% of isolates. Another common serotype
isolated in this study was serotype VI, which is rarely
reported in carriage studies from other parts of the
world. Interestingly this was the second most common
isolate in our study. The frequency of isolation of this
serotype was not significantly different to that in our
study (24.6% vs 16.7% p = 0.3).
One of the strengths of the current study is that GBS
serotyping was performed on both culture isolates and
PCR positive isolates giving an accurate picture of sero-
type distribution in this population.
An ongoing study in the same population will define
the incidence of early onset neonatal sepsis and the spe-
cific role of GBS, with the aim to combine the results of
both studies in order to formulate a preventative strat-
egy for GBS neonatal sepsis.
Conclusions
GBS carriage is not uncommon in pregnant women living
on the Thai-Myanmar border with a large range of sero-
types represented. These data are important for future glo-
bal GBS vaccine development and implementation.
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